AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29568986 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 103
Study 27135460 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (1 hour of total instruction during a 3-month period)
Number of subjects: 22
Study 27135460 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 22
Study 25209188 — intervention group
Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) intervention
Number of subjects: 2160
Study 25209188 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2160
Study 23062747 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component programme with clinical, educational and organizational procedures including primary care nurses as case-managers
Number of subjects: 338
Study 20214714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual education group
Number of subjects: 100
Study 20214714 — intervention group
Group type: COMPARATOR
Intervention: Nonsexual education group
Number of subjects: 100
Study 18068515 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 148
Study 18068515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 15753149 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 mcg l-selenomethionine)
Number of subjects: 32400
Study 15753149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg of racemic alpha-tocopheryl)
Number of subjects: 32400
Study 15753149 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E (combined)
Number of subjects: 32400
Study 15753149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32400
Study 11728984 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 50 U/kg by subcutaneous injection 3 times per week
Number of subjects: 21
Study 11728984 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 50 U/kg IV injection and AG 200 mg every other day by mouth
Number of subjects: 21
Study 11728984 — intervention group
Group type: COMPARATOR
Intervention: EPO 50 U/kg IV injection and placebo
Number of subjects: 21
Study 11728984 — intervention group
Group type: COMPARATOR
Intervention: Usual care without EPO
Number of subjects: 21
Study 9684134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 22
Study 9684134 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus Gentamicin
Number of subjects: 22
Study 8150356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation with 4 litres/minute for five minutes before sedation, followed by continuous oxygen administration.
Number of subjects: 50
Study 8150356 — intervention group
Group type: COMPARATOR
Intervention: No pre-oxygenation.
Number of subjects: 50
Study 3337037 — intervention group
Group type: COMPARATOR
Intervention: Diet without exercise (DO)
Number of subjects: 40
Study 3337037 — intervention group
Group type: COMPARATOR
Intervention: Diet plus weight training (DPE)
Number of subjects: 40
Study 3337037 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study 3337037 — intervention group
Group type: COMPARATOR
Intervention: Weight training without diet (EO)
Number of subjects: 40
Study 28917619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Chlorhexidine Gluconate (CHG)
Number of subjects: 111
Study 28917619 — intervention group
Group type: COMPARATOR
Intervention: Sterile Water (Control)
Number of subjects: 111
Study 27166718 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg of hCG, intravenously
Number of subjects: 14
Study 27166718 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls, n=10)
Number of subjects: 14
Study 25429036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Number of subjects: 473
Study 25429036 — intervention group
Group type: COMPARATOR
Intervention: Delayed therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Number of subjects: 473
Study 25429036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 473
Study 23692648 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of sessions concerning sports, parental involvement, individual counselling, lifestyle advice including dietary advice and cognitive behavioural therapy for 18 months.
Number of subjects: 104
Study 23692648 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 104
Study 20673506 — intervention group
Group type: EXPERIMENTAL
Intervention: BSD2000 deep hyperthermia combined with chemotherapy (paclitaxel: 135 mg/m2 ivdirp 3 h qd d1 + cisplatin: 20 mg/m2 ivdirp qd d1-5)
Number of subjects: 60
Study 20673506 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel and cisplatin)
Number of subjects: 60
Study 18216572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome
Number of subjects: 38
Study 18216572 — intervention group
Group type: COMPARATOR
Intervention: IntraLase femtosecond laser
Number of subjects: 38
Study 16624686 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone prescribed at discharge
Number of subjects: 9165
Study 14661009 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 4 mg/d
Number of subjects: 406
Study 14661009 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline treatment alone)
Number of subjects: 406
Study 14998239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare stimulus (short and more intense vibration)
Number of subjects: 8
Study 14998239 — intervention group
Group type: COMPARATOR
Intervention: Frequent stimulus (long and less intense vibration)
Number of subjects: 8
Study 14998239 — intervention group
Group type: COMPARATOR
Intervention: No stimulus
Number of subjects: 8
Study 14998239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare stimulus
Number of subjects: 8
Study 14998239 — intervention group
Group type: COMPARATOR
Intervention: Frequent stimulus
Number of subjects: 8
Study 10079417 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency exercise training (10 sessions per week)
Number of subjects: 130
Study 10079417 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency exercise training (2 sessions per week)
Number of subjects: 130
Study 7484034 — intervention group
Group type: COMPARATOR
Intervention: 0.5% prilocaine with methylparaben (Citanest)
Number of subjects: 200
Study 7484034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% prilocaine without methylparaben
Number of subjects: 200
Study 2124180 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enantate 50 mg with estradiol valerate 5 mg (monthly injectable contraceptive)
Number of subjects: 42
Study 2124180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 6153846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetracycline hydrochloride (Amphocycline)
Number of subjects: 15
Study 6153846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetracycline hydrochloride with 10% ethyl lactate solution applied twice daily
Number of subjects: 15
Study 6153846 — intervention group
Group type: COMPARATOR
Intervention: Local application of ethyl lactate solution only
Number of subjects: 15
Study 27503905 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg/mL three times weekly (GA40)
Number of subjects: 1041
Study 27503905 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the PC phase, then GA40 during the OL phase (DS group)
Number of subjects: 1041
Study 25929558 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardian Laryngeal Mask Airway (G‐LMA)
Number of subjects: 80
Study 25929558 — intervention group
Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (P‐LMA)
Number of subjects: 80
Study 23321934 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention
Number of subjects: 16
Study 23321934 — intervention group
Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 16
Study 21410839 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ in situ gel (0.8% metronidazole), applied twice daily for 5 days
Number of subjects: 42
Study 21410839 — intervention group
Group type: COMPARATOR
Intervention: Conventional vaginal gel product, applied twice daily for 5 days
Number of subjects: 42
Study 19561037 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 233
Study 19561037 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 233
Study 19561037 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 233
Study 19561037 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (12‐16 mg i.v. on day 1, 8 mg i.v. on day 2, and 4‐8 mg i.v. on day 3)
Number of subjects: 233
Study 17602038 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg intrathecal bupivacaine
Number of subjects: 52
Study 17602038 — intervention group
Group type: COMPARATOR
Intervention: 12 mg intrathecal bupivacaine
Number of subjects: 52
Study 15106360 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human follicle stimulating hormone (rhFSH) (Gonal‐F, Serono)
Number of subjects: 20
Study 15106360 — intervention group
Group type: COMPARATOR
Intervention: urinary human FSH (uhFSH) (Metrodin, Serono)
Number of subjects: 20
Study 11528569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (1 g given weekly)
Number of subjects: 464
Study 11528569 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin G (1.2 million U)
Number of subjects: 464
Study 9771865 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast provided every school day for 1 school year
Number of subjects: 814
Study 9771865 — intervention group
Group type: COMPARATOR
Intervention: Control group (one-quarter of an orange and same attention as breakfast group)
Number of subjects: 814
Study 9771865 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast provided
Number of subjects: 814
Study 9771865 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 814
Study 7837215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 293
Study 7837215 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 293
Study 3277450 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy with experienced clinicians
Number of subjects: 61
Study 3277450 — intervention group
Group type: COMPARATOR
Intervention: Mutual‐help group treatment led by nonclinicians
Number of subjects: 61
Study 3277450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Brief dynamic psychotherapy and Mutual-help group treatment)
Number of subjects: 61
Study 3277450 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup who completed the majority of sessions
Number of subjects: 61
Study 30738706 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 4775
Study 30738706 — intervention group
Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 4775
Study 30738706 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risks of CEA and CAS
Number of subjects: 4775
Study 28363636 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM265 (150 mg)
Number of subjects: 82
Study 28363636 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (10 mg/kg)
Number of subjects: 82
Study 28363636 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM265
Number of subjects: 82
Study 26431662 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg adefovir dipivoxil capsules once daily
Number of subjects: 102
Study 26431662 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg adefovir dipivoxil capsules once daily + 5 million U Recombinant Human Interferon α‐2b every other day
Number of subjects: 102
Study 26431662 — intervention group
Group type: COMPARATOR
Intervention: 10mg adefovir dipivoxil capsules once daily (control group)
Number of subjects: 102
Study 23422375 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 28
Study 23422375 — intervention group
Group type: COMPARATOR
Intervention: Saline administration (Control)
Number of subjects: 28
Study 20700581 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight (50-90 kg)
Number of subjects: 64
Study 20700581 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight changes up to 5 kg
Number of subjects: 64
Study 20700581 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine BMD
Number of subjects: 64
Study 20700581 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck BMD
Number of subjects: 64
Study 20700581 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip BMD
Number of subjects: 64
Study 19648681 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT before BiPAP treatment
Number of subjects: 90
Study 19648681 — intervention group
Group type: COMPARATOR
Intervention: BiPAP treatment after conventional anti-infection, phlegm treatment and support treatment
Number of subjects: 90
Study 17455407 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/Kg fentanyl IV
Number of subjects: 141
Study 17455407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg/Kg sufentanil IV
Number of subjects: 141
Study 17455407 — intervention group
Group type: COMPARATOR
Intervention: 2 ml isotonic normal saline (Control)
Number of subjects: 141
Study 15155117 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 15155117 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study 12414877 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI (quantitative insulin sensitivity check index)
Number of subjects: 208
Study 12414877 — intervention group
Group type: COMPARATOR
Intervention: QUICKI tertiles
Number of subjects: 208
Study 12414877 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 208
Study 12414877 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance measured by HOMA
Number of subjects: 208
Study 12414877 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal IMT of the CCA
Number of subjects: 208
Study 12414877 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CCA atherosclerosis
Number of subjects: 208
Study 12414877 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure and HDL cholesterol
Number of subjects: 208
Study 9809097 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% low molecular weight HES (MW 120,000/0.7) at 20 vol.%
Number of subjects: 10
Study 9809097 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low molecular weight HES (MW 200,000/0.5) at 20 vol.%
Number of subjects: 10
Study 9809097 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% high molecular weight HES (MW 400,000/0.7) at 20 vol.%
Number of subjects: 10
Study 9809097 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate at 20 vol.%
Number of subjects: 10
Study 9809097 — intervention group
Group type: COMPARATOR
Intervention: 4% albumin at 20 vol.%
Number of subjects: 10
Study 9809097 — intervention group
Group type: EXPERIMENTAL
Intervention: All solutions at 50 vol.%
Number of subjects: 10
Study 9809097 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 400 at 50 vol.%
Number of subjects: 10
Study 9809097 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200 at 50 vol.%
Number of subjects: 10
Study 7635125 — intervention group
Group type: EXPERIMENTAL
Intervention: Short system response times (SRTs of 0.5s)
Number of subjects: 40
Study 7635125 — intervention group
Group type: EXPERIMENTAL
Intervention: Long system response times (SRTs of 4.5s)
Number of subjects: 40
Study 7635125 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-incentive)
Number of subjects: 40
Study 7635125 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 40
Study 2676967 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) at an average maximal daily dose of 4.6 +/- 0.2 mg/kg
Number of subjects: 62
Study 2676967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 365323 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg three times a day)
Number of subjects: 211
Study 365323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 31510992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-scoring system for NLBP risk assessment
Number of subjects: 1439
Study 28675067 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (NeoTMZ) 200 mg/m2 days 1-5 every 28 days followed by RT 60 Gy in 30 fractions
Number of subjects: 144
Study 28675067 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (RT) only
Number of subjects: 144
Study 28675067 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (NeoTMZ) for AA patients
Number of subjects: 144
Study 28675067 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (RT) for AA patients
Number of subjects: 144
Study 28675067 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (NeoTMZ) for GBM patients
Number of subjects: 144
Study 28675067 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (RT) for GBM patients
Number of subjects: 144
Study 24844580 — intervention group
Group type: EXPERIMENTAL
Intervention: NIM‐Response 3.0 system
Number of subjects: 252
Study 24844580 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique using the Vari‐Stim 3
Number of subjects: 252
Study 23742808 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised version of Change Your Drinking
Number of subjects: 595
Study 23742808 — intervention group
Group type: COMPARATOR
Intervention: Original version of Change Your Drinking
Number of subjects: 595
Study 22019520 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Number of subjects: 148
Study 22019520 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Number of subjects: 148
Study 22019520 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy
Number of subjects: 148
Study 19358086 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of power and balance
Number of subjects: 159
Study 19358086 — intervention group
Group type: COMPARATOR
Intervention: Control group (different hospital)
Number of subjects: 159
Study 19358086 — intervention group
Group type: COMPARATOR
Intervention: Patients treated in the year before
Number of subjects: 159
Study 16948115 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg plus MTX
Number of subjects: 299
Study 16948115 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg plus MTX
Number of subjects: 299
Study 16948115 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 299
Study 15361763 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (10 micromol/min)
Number of subjects: 40
Study 15361763 — intervention group
Group type: COMPARATOR
Intervention: N-monomethyl-L-arginine (L-NMMA; 4 micromol/min)
Number of subjects: 40
Study 15361763 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (9 and 37 microg/min)
Number of subjects: 40
Study 15361763 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (200 and 800 ng/min)
Number of subjects: 40
Study 15361763 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (50 and 200 ng/min)
Number of subjects: 40
Study 12575372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheitis Plaster (TP) applied on acupoints Dingchuan, Dashu, Fengmen, Feishu and Xinshu at back along both sides of thoracic vertebrae 1‐6, treatment duration: 20 times.
Number of subjects: 84
Study 12575372 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of Siqikang, treatment duration: 20 times.
Number of subjects: 84
Study 9051545 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 202
Study 9051545 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation
Number of subjects: 202
Study 8326288 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 7
Study 8326288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3549096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray (200 units daily)
Number of subjects: 36
Study 3549096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray (400 units daily)
Number of subjects: 36
Study 3549096 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository (300 units)
Number of subjects: 36
Study 3549096 — intervention group
Group type: COMPARATOR
Intervention: Parenteral route
Number of subjects: 36
Study 3549096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31509844 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol-betamethasone ointment
Number of subjects: 0
Study 31509844 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 29265563 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention to improve physical activity levels
Number of subjects: 1564
Study 29265563 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 1564
Study 29265563 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention
Number of subjects: 1564
Study 27473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg every 4 weeks for up to six injections)
Number of subjects: 696
Study 27473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 plus abiraterone or enzalutamide
Number of subjects: 696
Study 27473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 plus denosumab
Number of subjects: 696
Study 27473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Any-grade treatment-emergent adverse events
Number of subjects: 696
Study 27473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 696
Study 27473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 or worse treatment-related adverse events
Number of subjects: 696